Jan 14, 2020 / 04:30PM GMT
Yuko Oku - JP Morgan Chase & Co, Research Division - Analyst
Hi. I'm Yuko Oku, one of the associates on the biotech team at JPMorgan. It's a pleasure to welcome Denali to the JPMorgan Conference. A quick housekeeping note before we begin, we'll be holding a Q&A session right after the presentation in the Georgian room just across the hall.
With that, I'd like to turn it over to CEO, Ryan Watts.
Ryan J. Watts - Denali Therapeutics Inc. - Co-Founder, President, CEO & Director
All right. It's exciting to be here again at JPMorgan, especially exciting today because we're presenting new data. A little bit unusual, we're going to go into some depth. I love data, we love data. We're going to share some clinical data, plus progress in the portfolio. But I'd like to start with a reminder, which is the huge unmet need we're trying to tackle. We've seen incredible progress in oncology, rare disease, obviously, new modalities. Many of us, including myself, have worked in the oncology space, and now we're turning our attention to neurodegeneration. And
Denali Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers